Clinical Scorecard: Assessment of Treatment Strategies for Drug-Resistant Tuberculosis Across Various Regions: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Resistance to first-line anti-TB medications necessitates the use of second-line drugs, including fluoroquinolones and injectable agents.
Target Population
Care Setting
Key Highlights
treatment_success_rate
Guideline-Based Recommendations
Diagnosis
Management
Current WHO-recommended treatment strategies include a 6-month all-oral regimen, a 9-month all-oral regimen for non-fluoroquinolone resistant cases, and an extended course of 18-20 months with injections.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Shorter regimens are preferred, but longer courses may be necessary in complex cases, such as those with extensive drug resistance or previous treatment failures.
Clinical Best Practices
Utilize the 6-month all-oral regimen as the first-line treatment for MDR/RR-TB, and monitor for adverse events such as nausea, vomiting, and ototoxicity.
